(2023). Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification. Diabet Med, e15200. http://doi.org/10.1111/dme.15200
. H. Chen
First name
H.
Last name
Chen
(2022). Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01263-3
. (2022). Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01262-4
. (2022). Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility. Kidney Int Rep, 7, 2059-2070. http://doi.org/10.1016/j.ekir.2022.05.033
. (2016). Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension. J Alzheimers Dis. http://doi.org/10.3233/jad-150466
. (2019). Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. Am J Nephrol. http://doi.org/10.1159/000504558
.